Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018–2019 Influenza Season

Sakai‐Tagawa, Yuko; Yamayoshi, Seiya; Kawaoka, Yoshihiro

doi:10.3389/fmicb.2019.02342

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, RATs with superior sensitivity are useful for rapid diagnosis especially in limited resource settings where RT-qPCR is hard to perform, because they allow for immediate isolation of individuals shedding a large amount of virus. The sensitivity of influenza RATs has improved over time since their inception [23][24][25][26]; therefore, we anticipate that COVID-19 RATs that are more sensitive will be developed in the near future to support the control of COVID-19 and to help initiate treatment early after onset.…”

Section: Discussionmentioning

confidence: 99%

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2

Sakai‐Tagawa

Yamayoshi

Halfmann

et al. 2021

Viruses

Self Cite

View full text Add to dashboard Cite

Rapid antigen tests (RATs) for COVID-19 based on lateral flow immunoassays are useful for rapid diagnosis in a variety of settings. Although many kinds of RATs are available, their respective sensitivity has not been compared. Here, we examined the sensitivity of 27 RATs available in Japan for the detection of the SARS-CoV-2 delta variant. All of the RATs tested detected the delta variant albeit with different sensitivities. Nine RATs (ESPLINE SARS-CoV-2, ALSONIC COVID-19 Ag, COVID-19 and Influenza A+B Antigen Combo Rapid Test, ImmunoArrow SARS-CoV-2, Fuji Dri-chem immuno AG cartridge COVID-19 Ag, 2019-nCoV Ag rapid detection kit, Saliva SARS-CoV-2(2019-nCoV) Antigen Test Kit, and Rabliss SARS-CoV-2 antigen detection kit COVID19 AG) showed superior sensitivity to the isolated delta variant. Although actual clinical specimens were not examined, the detection level of most of the RATs was 7500 pfu, indicating that individuals whose test samples contained less virus than that would be considered negative. Therefore, it is important to bear in mind that RATs may miss individuals shedding low levels of infectious virus.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2

Sakai‐Tagawa

Yamayoshi

Halfmann

et al. 2021

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…For the diagnosis of influenza, a variety of IRDTs, which are easy, rapid, and low cost, are currently widely used in Japan, and likely the most commonly-used influenza confirmatory tests captured in our study. The sensitivity of IRDTs for seasonal influenza B viruses is lower or similar compared to that of seasonal influenza A viruses [32]. The reported sensitivities of IRDTs for influenza viruses in general ranges between 10%-80%, with lower sensitivity observed among older adults and in those with underlying conditions [14,[33][34][35].…”

Section: Plos Onementioning

confidence: 99%

Seasonal influenza, its complications and related healthcare resource utilization among people 60 years and older: A descriptive retrospective study in Japan

et al. 2022

View full text Add to dashboard Cite

Evidence suggests that older people aged ≥65 years and those aged 60–64 years with chronic medical conditions are at higher risk of developing severe complications due to influenza virus infection when compared with young, healthy adults. Although seasonal influenza is monitored through a nationwide passive surveillance in Japan, influenza related outcomes and medical resource consumption have not been fully documented. This retrospective database study aimed to describe the epidemiological and clinical characteristics of medically attended influenza cases aged ≥60 years and the associated medical resource consumption in Japan. We used clinically diagnosed influenza (CDI) based on the international classification of disease codes, and laboratory-confirmed influenza (LCI) based on influenza test results, to identify the patient population during a total of nine seasons (2010/2011 to 2018/2019). A total of 372,356 CDI and 31,122 LCI cases were identified from 77 medical institutions. The highest numbers of medically-attended influenza episodes were in patients aged 65–74 years and 75–84 years. On average, across seasons, 5.9% of all-cause hospitalizations were attributable to CDI and 0.4% were LCI. Influenza viruses type A and B co-circulated annually in varying degree of intensity and were associated with similar level of complications, including cardiovascular-related. Oxygen therapy increased with age; by contrast, mechanical ventilation, dialysis, blood transfusion, and intensive care unit admission were higher in the younger groups. In-hospital mortality for inpatients aged ≥ 85 years with CDI and LCI were 18.6% and 15.5%, respectively. Considering the burden associated with medically-attended influenza in this population, influenza prevention, laboratory confirmation and clinical management should be emphasized by general practicians and specialists like cardiologists to protect this aging population.

show abstract

“…[9] LFIA, typically used in rapid influenza diagnostic tests (rapid kits), takes advantage of the localized surface plasmon resonance (LSPR) properties of gold nanoparticles (GNPs) in the detection of viruses, leading to rapid results via simple analysis [9] and an extremely high detection limit as compared to other methods. [10,11] However, all three methods detect viral components only (proteins or RNA) and the selective detection of infectious virions (intact, active viruses) remains challenging. For influenza viruses to possess infectivity, they must be intact, whole virions that can fuse with host cells and replicate their viral genomes.…”

Section: Introductionmentioning

confidence: 99%

Label‐Free and Colorimetric Detection of Influenza A Virus via Receptor‐Mediated Viral Fusion with Plasmonic Vesicles

Moon,

Lee,

Kim

et al. 2023

Small

View full text Add to dashboard Cite

The rapid transmission and numerous re‐emerging human influenza virus variants that spread via the respiratory system have led to severe global damage, emphasizing the need for detection tools that can recognize active and intact virions with infectivity. Here, this work presents a plasmonic vesicle‐mediated fusogenic immunoassay (PVFIA) comprising gold nanoparticle (GNP) encapsulating fusogenic polymeric vesicles (plasmonic vesicles; PVs) for the label‐free and colorimetric detection of influenza A virus (IAV). The PVFIA combines two sequential assays: a biochip‐based immunoassay for target‐specific capture and a PV‐induced fusion assay for color change upon the IAV–PV fusion complex formation. The PVFIA demonstrates excellent specificity in capturing the target IAV, while the fusion conditions and GNP induce a significant color change, enabling visual detection. The integration of two consecutive assays results in a low detection limit (100.7919 EID50 mL−1) and good reliability (0.9901), indicating sensitivity that is 104.208 times higher than conventional immunoassay. Leveraging the PV viral membrane fusion activity renders the PVFIA promising for point‐of‐care diagnostics through colorimetric detection. The innovative approach addresses the critical need for detecting active and intact virions with infectivity, providing a valuable tool with which to combat the spread of the virus.

show abstract

Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018–2019 Influenza Season

Cited by 5 publications

References 23 publications

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2

Seasonal influenza, its complications and related healthcare resource utilization among people 60 years and older: A descriptive retrospective study in Japan

Label‐Free and Colorimetric Detection of Influenza A Virus via Receptor‐Mediated Viral Fusion with Plasmonic Vesicles

Contact Info

Product

Resources

About